IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.